Thomas Powles, MD

Articles

Improving Patient Communication and Treatment Decisions with ctDNA Monitoring in MIBC

December 8th 2025

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

Integrating ctDNA-Based MRD Testing in MIBC

December 8th 2025

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Unmet Needs and the Evolving Role of MRD Monitoring in MIBC

December 1st 2025

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Risk Stratification and Surveillance After

December 1st 2025

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Analyzing the Role of ctDNA and Adjuvant

November 20th 2025

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Biomarker, Diagnosis, and Evolving Treatment Paradigm in MIBC

November 20th 2025

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Advancements in Perioperative Therapy for MIBC

November 13th 2025

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Novel Neoadjuvant Therapies in MIBC

November 13th 2025

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Dr Powles on EFS With Sasanlimab Plus BCG in BCG-Naive, High-Risk NMIBC

May 31st 2025

Thomas Powles, MD, MBBS, MRCP, shares data from an EFS subgroup analysis from the phase 3 CREST study in BCG-naive, high-risk NMIBC.

Dr Powles on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer

January 16th 2024

Thomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.

Future Directions in the Management of Renal Cell Carcinoma

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy

November 3rd 2022

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond

October 27th 2022

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?

October 27th 2022

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

October 20th 2022

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.